UA77234C2 - Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants) - Google Patents
Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants) Download PDFInfo
- Publication number
- UA77234C2 UA77234C2 UA20040705309A UA20040705309A UA77234C2 UA 77234 C2 UA77234 C2 UA 77234C2 UA 20040705309 A UA20040705309 A UA 20040705309A UA 20040705309 A UA20040705309 A UA 20040705309A UA 77234 C2 UA77234 C2 UA 77234C2
- Authority
- UA
- Ukraine
- Prior art keywords
- venlafaxine hydrochloride
- mammal
- effective amount
- monohydrate
- administering
- Prior art date
Links
- 229960002416 venlafaxine hydrochloride Drugs 0.000 title claims abstract description 98
- QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 title claims abstract description 98
- 238000000034 method Methods 0.000 title claims abstract description 33
- 150000004682 monohydrates Chemical class 0.000 title abstract description 17
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 32
- 241000124008 Mammalia Species 0.000 claims description 31
- 230000004048 modification Effects 0.000 claims description 28
- 238000012986 modification Methods 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 20
- 238000002441 X-ray diffraction Methods 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
- 238000001953 recrystallisation Methods 0.000 claims description 4
- 238000005550 wet granulation Methods 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 230000001430 anti-depressive effect Effects 0.000 claims description 3
- 239000000935 antidepressant agent Substances 0.000 claims description 3
- 229940005513 antidepressants Drugs 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 208000019906 panic disease Diseases 0.000 claims description 3
- 230000011273 social behavior Effects 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims 1
- 229960004688 venlafaxine Drugs 0.000 description 17
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 238000004090 dissolution Methods 0.000 description 8
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000002411 thermogravimetry Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000018044 dehydration Effects 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000002336 sorption--desorption measurement Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- -1 brighteners Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000037410 cognitive enhancement Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002267 hypothalamic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001272 neurogenic effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000022497 Cocaine-Related disease Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000006145 cocaine dependence Diseases 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000001544 dysphoric effect Effects 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000742 histaminergic effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- FBBDOOHMGLLEGJ-UHFFFAOYSA-N methane;hydrochloride Chemical compound C.Cl FBBDOOHMGLLEGJ-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000003901 neurotransmitter uptake inhibitor Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 208000002271 trichotillomania Diseases 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33582301P | 2001-12-05 | 2001-12-05 | |
| PCT/US2002/038581 WO2003050076A1 (en) | 2001-12-05 | 2002-12-03 | Venlafaxine hydrochloride monohydrate and methods for the preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA77234C2 true UA77234C2 (en) | 2006-11-15 |
Family
ID=23313363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20040705309A UA77234C2 (en) | 2001-12-05 | 2002-03-12 | Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants) |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20030114536A1 (pl) |
| EP (1) | EP1451146A1 (pl) |
| JP (1) | JP2005511737A (pl) |
| KR (1) | KR20050044711A (pl) |
| CN (1) | CN1599715A (pl) |
| AR (1) | AR037636A1 (pl) |
| AU (1) | AU2002366574A1 (pl) |
| BR (1) | BR0214696A (pl) |
| CA (1) | CA2467614A1 (pl) |
| CO (1) | CO5580817A2 (pl) |
| EC (1) | ECSP045134A (pl) |
| HU (1) | HUP0402553A2 (pl) |
| MX (1) | MXPA04005307A (pl) |
| NO (1) | NO20042810L (pl) |
| PL (1) | PL370559A1 (pl) |
| RU (1) | RU2004120273A (pl) |
| TW (1) | TW200300669A (pl) |
| UA (1) | UA77234C2 (pl) |
| WO (1) | WO2003050076A1 (pl) |
| ZA (1) | ZA200405245B (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1630631A (zh) * | 2001-12-05 | 2005-06-22 | 惠氏公司 | 新的文拉法星盐酸盐多晶型物及其制备方法 |
| CA2574315A1 (en) * | 2004-07-22 | 2006-02-02 | Wyeth | Method for treating nervous system disorders and conditions |
| US20060020015A1 (en) * | 2004-07-22 | 2006-01-26 | Wyeth | Method for treating nervous system disorders and conditions |
| AU2005266997A1 (en) * | 2004-07-22 | 2006-02-02 | Wyeth | Method for treating nervous system disorders and conditions |
| KR20080056311A (ko) * | 2005-10-19 | 2008-06-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 고순도1-[2-디메틸아미노-(4-메톡시페닐)에틸)시클로헥산올염산염의 제조 방법 |
| CN101484411A (zh) | 2006-06-27 | 2009-07-15 | 桑多斯股份公司 | 盐的新制备方法 |
| EP2357183B1 (en) | 2007-05-01 | 2015-07-01 | Concert Pharmaceuticals Inc. | Morphinan compounds |
| US20120083487A1 (en) * | 2008-10-30 | 2012-04-05 | Amanda Thomas | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurolgical diseases, intractable and chronic pain and brain injury |
| CA2995395C (en) | 2015-08-31 | 2024-04-16 | Nutramax Laboratories, Inc. | Compositions comprising magnolia, phellodendron, theanine and/or whey protein |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69429895T2 (de) * | 1993-06-28 | 2002-08-29 | American Home Products Corp., Madison | Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten |
| TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
| US5530013A (en) * | 1994-02-14 | 1996-06-25 | American Home Products Corporation | Venlafaxine in the inducement of cognition enhancement |
| US5506270A (en) * | 1995-01-30 | 1996-04-09 | American Home Products Corporation | Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women |
| US6274171B1 (en) * | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| US20020183553A1 (en) * | 2000-10-19 | 2002-12-05 | Ben-Zion Dolitzky | Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof |
| KR20030059206A (ko) * | 2000-10-19 | 2003-07-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 결정질 벤라팍신 염기 및 벤라팍신 히드로클로라이드의신규한 다형태, 이의 제조 방법 |
| AU2002212340B2 (en) * | 2000-10-31 | 2006-12-14 | Sandoz Ag | Crystalline forms of venlafaxine hydrochloride |
| WO2002046140A1 (en) * | 2000-12-07 | 2002-06-13 | Dr. Reddy's Laboratories Ltd. | Novel crystalline polymorphic forms of venlafaxine hydrochloride and a process for their preparation |
-
2002
- 2002-03-12 UA UA20040705309A patent/UA77234C2/uk unknown
- 2002-12-03 US US10/308,472 patent/US20030114536A1/en not_active Abandoned
- 2002-12-03 JP JP2003551103A patent/JP2005511737A/ja not_active Withdrawn
- 2002-12-03 MX MXPA04005307A patent/MXPA04005307A/es unknown
- 2002-12-03 PL PL02370559A patent/PL370559A1/pl not_active Application Discontinuation
- 2002-12-03 KR KR1020047008653A patent/KR20050044711A/ko not_active Withdrawn
- 2002-12-03 RU RU2004120273/04A patent/RU2004120273A/ru not_active Application Discontinuation
- 2002-12-03 EP EP02791360A patent/EP1451146A1/en not_active Withdrawn
- 2002-12-03 WO PCT/US2002/038581 patent/WO2003050076A1/en not_active Ceased
- 2002-12-03 TW TW091135029A patent/TW200300669A/zh unknown
- 2002-12-03 HU HU0402553A patent/HUP0402553A2/hu unknown
- 2002-12-03 CA CA002467614A patent/CA2467614A1/en not_active Abandoned
- 2002-12-03 CN CNA028242394A patent/CN1599715A/zh active Pending
- 2002-12-03 BR BR0214696-7A patent/BR0214696A/pt not_active IP Right Cessation
- 2002-12-03 AU AU2002366574A patent/AU2002366574A1/en not_active Abandoned
- 2002-12-04 AR ARP020104687A patent/AR037636A1/es not_active Application Discontinuation
-
2004
- 2004-06-01 CO CO04050940A patent/CO5580817A2/es not_active Application Discontinuation
- 2004-06-04 EC EC2004005134A patent/ECSP045134A/es unknown
- 2004-07-01 ZA ZA200405245A patent/ZA200405245B/xx unknown
- 2004-07-02 NO NO20042810A patent/NO20042810L/no not_active Application Discontinuation
-
2005
- 2005-08-05 US US11/198,041 patent/US20050272822A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2004120273A (ru) | 2005-03-27 |
| ZA200405245B (en) | 2007-01-31 |
| AU2002366574A1 (en) | 2003-06-23 |
| TW200300669A (en) | 2003-06-16 |
| NO20042810L (no) | 2004-07-02 |
| PL370559A1 (pl) | 2005-05-30 |
| EP1451146A1 (en) | 2004-09-01 |
| US20030114536A1 (en) | 2003-06-19 |
| BR0214696A (pt) | 2004-11-03 |
| CN1599715A (zh) | 2005-03-23 |
| AR037636A1 (es) | 2004-11-17 |
| CA2467614A1 (en) | 2003-06-19 |
| MXPA04005307A (es) | 2004-09-13 |
| US20050272822A1 (en) | 2005-12-08 |
| WO2003050076A1 (en) | 2003-06-19 |
| KR20050044711A (ko) | 2005-05-12 |
| JP2005511737A (ja) | 2005-04-28 |
| HUP0402553A2 (hu) | 2005-03-29 |
| CO5580817A2 (es) | 2005-11-30 |
| ECSP045134A (es) | 2004-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7086118B2 (ja) | Ｌ－オルニチンフェニルアセテートおよびその製造方法 | |
| US20100010098A1 (en) | Polymorphs of rasagiline hydrochloride | |
| US20090005457A1 (en) | Solid forms comprising (-)-O-desmethylvenlafaxine and uses thereof | |
| UA77234C2 (en) | Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants) | |
| US7030164B2 (en) | Crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof | |
| US20090291953A1 (en) | Pharmaceutical salts of reboxetine | |
| KR101404836B1 (ko) | 아고멜라틴의 공결정 및 그의 제조방법 | |
| EA030553B1 (ru) | Тапентадола малеат и его кристаллические формы | |
| HK1120035A (en) | Pharmaceutical salts of reboxetine | |
| HK1071884A (en) | Venlafaxine hydrochloride monohydrate and methods for the preparation thereof | |
| HK1077572B (en) | Pharmaceutical salts of reboxetine |